美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

中國生物製藥ADR

18.22

0.0000

成交量：3.00

成交額：52.72

市值：165.85億

市盈率：34.77

高：18.22

開：18.22

低：18.22

收：18.22

52周最高：20.16

52周最低：7.15

股本：9.10億

流通股本：4.58億

量比：0.02

換手率：NaN%

股息：0.23

股息率：1.29%

每股收益(TTM):0.5241

每股收益(LYR):0.5242

淨資產收益率：15.40%

總資產收益率：5.07%

市淨率：3.51

市盈率(LYR):34.76

資料載入中...

總覽公司新聞資訊公告

脱髮新藥III期成功；創新藥出海新模式誕生

利好密集來襲！創新藥概念大爆發

东方财富研究中心

2025年西藥行業市場發展現狀趨勢分析

中國生物製藥又一款 1 類新藥首次啓動臨牀

丁香园 Insight 数据库

中國生物製藥(1177HK)：PDE3/4抑制劑II期臨牀數據亮眼市場潛力巨大

大健康行業週報 |13億，「中國美敦力」完成交割；東星醫療：擬以支付現金方式購買武漢醫佳寶90%的股權

華源證券-醫藥行業週報信立泰：全面佈局CKM管線，創新出海加速推進-250928

創新藥中場覆盤：泡沫擠壓後的新起點

Ofweek维科网

中國生物製藥：TQB3122「PARP1抑制劑」臨牀試驗申請獲NMPA受理

中國生物製藥阿達木單抗在阿爾及利亞獲批上市

中國生物製藥下跌4.48%，報7.03元/股

生物醫藥行業研究報告：各部門合力推進商保建設助力創新藥械發展

醫藥行業週報：禮來口服減肥藥療效低於預期關注中國創新減肥藥研發和出海進展

醫藥行業週報：中藥、生物製品、測序及醫藥商業行業觀點更新

中信建投证券

中國生物製藥8月7日成交額為131.00美元

【研報】生物製藥板塊深度分析報告：資本介入、政策支持與研發驅動

上市公司网

中國生物製藥下跌2.93%，報7.28元/股

中國生物製藥：羅伐昔替尼Ⅲ期試驗正招募受試者

國藥之光安羅替尼領銜中國生物製藥13項肺癌成果閃耀世界舞台

中國生物製藥8月5日成交額為261.00美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SBHMY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBHMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBHMY\",,,,,undefined,":{"symbol":"SBHMY","market":"US","secType":"STK","nameCN":"中國生物製藥ADR","latestPrice":18.22,"timestamp":1764949306151,"preClose":18.22,"halted":0,"volume":3,"delay":15,"floatShares":457950931,"shares":910273459,"eps":0.524054,"marketStatus":"休市中","change":0,"latestTime":"12-05 10:41:46 EST 延時","open":18.22,"high":18.22,"low":18.22,"amount":52.724999999999994,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.524054,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":20,"exchange":"PINK LIMITED","adjPreClose":18.22,"volumeRatio":0.023622049104098354},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBHMY\",,,,,undefined,":{"symbol":"SBHMY","floatShares":457950931,"roa":"5.07%","roe":"15.40%","lyrEps":0.524215,"volumeRatio":0.023622049104098354,"shares":910273459,"dividePrice":0.23481,"high":18.22,"amplitude":0,"preClose":18.22,"low":18.22,"week52Low":7.15,"pbRate":"3.51","psRate":"3.83","week52High":20.16,"institutionHeld":0,"latestPrice":18.22,"eps":0.524054,"divideRate":0.012887,"volume":3,"delay":15,"ttmEps":0.524054,"open":18.22,"prevYearClose":8.335,"prevWeekClose":18.22,"prevMonthClose":18.22,"prevQuarterClose":20.16,"fiveDayClose":18.22,"twentyDayClose":19.445,"sixtyDayClose":20.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBHMY\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"SBHMY","amount":0.127855,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-29","defaultRemindTime":1756474200000,"name":"中国生物制药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-08","payableDate":"2025-08-29","currency":"USD","dateTimestamp":1756440000000,"payDate":"2025-10-08"},{"date":"2025-06-17","symbol":"SBHMY","amount":0.102066,"announcedDate":"2025-05-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-17","defaultRemindTime":1750167000000,"name":"中国生物制药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-25","payableDate":"2025-06-17","currency":"USD","dateTimestamp":1750132800000,"payDate":"2025-07-25"},{"date":"2024-09-12","symbol":"SBHMY","amount":0.065379,"announcedDate":"2024-08-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-12","defaultRemindTime":1726147800000,"name":"中国生物制药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-18","payableDate":"2024-09-12","currency":"USD","dateTimestamp":1726113600000,"payDate":"2024-10-18"},{"date":"2024-09-11","symbol":"SBHMY","amount":0.076916,"announcedDate":"2024-08-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-11","defaultRemindTime":1726061400000,"name":"中国生物制药ADR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-18","payableDate":"2024-09-11","currency":"USD","dateTimestamp":1726027200000,"payDate":"2024-10-18"},{"date":"2024-06-12","symbol":"SBHMY","amount":0.076829,"announcedDate":"2024-05-29","type":"dividend","market":"US","newRecordDate":"2024-06-12","defaultRemindTime":1718199000000,"name":"中国生物制药ADR","recordDate":"2024-07-22","payableDate":"2024-06-12","currency":"USD","dateTimestamp":1718164800000,"payDate":"2024-07-22"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBHMY\",market:\"US\",,,undefined,":[{"executeDate":"2018-09-10","recordDate":"2018-09-11","paymentDate":"2018-10-15","value":0.040958,"currency":"USD"},{"executeDate":"2018-12-04","recordDate":"2018-12-05","paymentDate":"2019-01-07","value":0.041124,"currency":"USD"},{"executeDate":"2019-06-13","recordDate":"2019-06-14","paymentDate":"2019-07-19","value":0.040963,"currency":"USD"},{"executeDate":"2019-09-11","recordDate":"2019-09-12","paymentDate":"2019-10-15","value":0.040986,"currency":"USD"},{"executeDate":"2019-12-09","recordDate":"2019-12-10","paymentDate":"2020-01-13","value":0.041103,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBHMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.36,"buy":0.6,"hold":0.04,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":25,"updateTime":1758603600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBHMY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589829615","title":"脱髮新藥III期成功；創新藥出海新模式誕生","url":"https://stock-news.laohu8.com/highlight/detail?id=2589829615","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589829615?lang=zh_tw&edition=fundamental","pubTime":"2025-12-06 17:01","pubTimestamp":1765011660,"startTime":"0","endTime":"0","summary":"科伦博泰与Crescent达成“双向授权”交易，中国创新药出海再添新玩法；雄激素脱发新药III期临床成功，预计明年申报上市；中国药品价格登记系统上线，面向企业和全球开放查询；默克中国宣布重要任命；FDA再现人事动荡……若Crescent近期发生控制权变更或与第三方签订分许可协议，科伦博泰亦有资格向Crescent收取额外款项。阅读详情>>研发动态雄激素脱发新药III期成功12月4日，Cosmo Pharmaceuticals宣布，Clascoterone用于治疗男性雄激素性脱发的两项关键III期试验中取得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206170552a437ab11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206170552a437ab11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY","BK4134","III"],"gpt_icon":0},{"id":"2579462065","title":"利好密集來襲！創新藥概念大爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462065","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579462065?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:54","pubTimestamp":1761904444,"startTime":"0","endTime":"0","summary":"据证券时报报道，今年国家医保谈判在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。此外，年内国产创新药“出海”进程明显提速。根据医药魔方NextPharma数据库，截至10月21日，中国创新药今年对外许可共发生115起，金额总计达到1012.4亿美元，远超2024年全年的519亿美元。国信证券指出，中国创新药产业已经体现出长期向好的发展趋势，并在近年集中体现在BD交易的爆发式增长。配置上，看好创新药长期逻辑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY","06990","01952","09995","03759","02552"],"gpt_icon":0},{"id":"2579245144","title":"2025年西藥行業市場發展現狀趨勢分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2579245144","media":"中研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579245144?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:39","pubTimestamp":1761903584,"startTime":"0","endTime":"0","summary":"2025年西药行业市场发展现状趋势分析在人口老龄化加速、医疗技术革新与政策红利的三重驱动下，中国西药行业正经历从“规模扩张”到“质量跃升”的关键转型。据中研产业研究院《2025-2030年中国西药行业竞争分析及发展前景预测报告》分析二、西药产业链及市场规模1. 上游：原料药国产化与CDMO崛起原料药是西药产业的基石。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031173949a47fb7a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031173949a47fb7a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","LU1046422090.SGD","BK1161","LU0320764599.SGD","01276","01093","09969","06978","BK1141","06160","01801","LU0708995583.HKD","BK1574","03692","SBHMY","BK1576","LU0052750758.USD","LU2125910500.SGD","02359","09995","01177","LU2045819591.USD","LU2242644610.SGD","BK1583"],"gpt_icon":0},{"id":"2579167282","title":"中國生物製藥又一款 1 類新藥首次啓動臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2579167282","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579167282?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 14:12","pubTimestamp":1761804767,"startTime":"0","endTime":"0","summary":"10 月 29 日，中国药物临床试验登记与信息公示平台显示，中国生物制药旗下泰德制药1 类新药注射用 TRD208 启动首个临床试验。截图来源：药物临床试验登记与信息公示平台TRD208 是一款非阿片类双模式长效镇痛1 类创新药，融合了神经传导阻滞和抗炎的双重机制，临床前数据显示其对于中度急性疼痛具有显著获益。9 月，该药在国内获批临床，默示许可适应症为成人术后镇痛，并于近日正式启动临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030141540a6d61d5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030141540a6d61d5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1521","BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR","BK1589","SBHMY"],"gpt_icon":0},{"id":"2575288909","title":"中國生物製藥(1177HK)：PDE3/4抑制劑II期臨牀數據亮眼 市場潛力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2575288909","media":"招银国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575288909?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 00:00","pubTimestamp":1760284800,"startTime":"0","endTime":"0","summary":"中国生物制药在欧洲呼吸学会2025 年会上公布了其PDE3/4 抑制剂TQC3721 的II 期临床结果，临床结果显示TQC3721 可快速改善患者肺功能和症状。临床数据表明TQC3721 具备同类最佳潜力。PDE3/4 药物市场潜力巨大，竞争格局良好。默沙东在今年7 月宣布以100 亿美元收购Verona，体现PDE3/4 抑制剂巨大的市场潜力。作为全球进度第二且唯一处在III 期临床的PDE3/4 抑制剂，我们认为TQC3721 具备重磅海外授权潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY"],"gpt_icon":0},{"id":"2571800933","title":"大健康行業週報 |13億，「中國美敦力」完成交割；東星醫療：擬以支付現金方式購買武漢醫佳寶90%的股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2571800933","media":"保观","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571800933?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 12:04","pubTimestamp":1759118650,"startTime":"0","endTime":"0","summary":"保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","01276","03933","LU1993786604.SGD","LU1969619763.USD","BK1197","00570","IE00B5MMRT66.SGD","03320","LU2543165471.USD","LU0588546209.SGD","LU0072913022.USD","06160","LU0067412154.USD","LU1023057109.AUD","LU1226288170.HKD","IE0008368742.USD","00874","BK1606","LU0315179316.USD","LU1303224171.USD","LU1008478684.HKD","IE00B543WZ88.USD","BK1500","BK1570","03692","IE00BZ08YR35.GBP","LU1152091168.USD","BK1593","IE00B031HY20.USD","LU1226288253.USD","SG9999004220.SGD","LU0326950275.SGD","LU1719994722.HKD","SBHMY","LU1328277881.USD","01177","LU0359201885.HKD","LU1960683339.HKD","LU2328871848.SGD","01093","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1226287875.USD","LU1226287529.USD","02196","LU2039709279.SGD","LU1226287792.SGD","LU1251922891.USD","IE0008369823.USD"],"gpt_icon":0},{"id":"2571782687","title":"華源證券-醫藥行業週報信立泰：全面佈局CKM管線，創新出海加速推進-250928","url":"https://stock-news.laohu8.com/highlight/detail?id=2571782687","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571782687?lang=zh_tw&edition=fundamental","pubTime":"2025-09-28 23:02","pubTimestamp":1759071720,"startTime":"0","endTime":"0","summary":"全面布局CKM管线，创新出海加速推进。我们认为信立泰创新研发已经迎来重大蜕变，公司全面布局心血管-肾脏-代谢慢病领域，在研管线涵盖高血压、血脂异常、心衰、代谢、肾科等多个领域，并布局单抗、多抗、ADC、多肽、环肽、基因编辑等新型技术平台，多款产品已经进入到临床阶段，不断强化公司在中国慢病领域综合性龙头地位。我们看好信立泰基于心血管为核心的CKM创新管线布局，带动公司成长为中国综合性慢病领域创新药龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1152091754.HKD","09926","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","BK1161","LU1226287792.SGD","LU2543165471.USD","BK1583","03692","LU1226287875.USD","BK1515","SG9999004220.SGD","LU1023057109.AUD","LU1960683339.HKD","LU1226288253.USD","LU1008478684.HKD","LU0067412154.USD","LU0315179316.USD","IE00B543WZ88.USD","LU2039709279.SGD","LU1807302812.USD","LU0326950275.SGD","SBHMY","01177","BK1589","01093","LU0359202008.SGD","06978","IE0008368742.USD","IE0008369823.USD","LU0140636845.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU0359201885.HKD","BK1521","LU1951186391.HKD","LU0359201612.USD","LU1226288170.HKD","01276","LU1226287529.USD","LU1328277881.USD","LU0501845795.SGD","LU1993786604.SGD","IE00BZ08YT58.USD","LU0880133367.SGD","BK1191","LU1813983027.USD","IE00B031HY20.USD","BK1574","LU1152091168.USD"],"gpt_icon":0},{"id":"2566678767","title":"創新藥中場覆盤：泡沫擠壓後的新起點","url":"https://stock-news.laohu8.com/highlight/detail?id=2566678767","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566678767?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 15:08","pubTimestamp":1757488085,"startTime":"0","endTime":"0","summary":"在刚刚落幕的 WCLC，中国创新药企集中展示最新成果。随着二级市场回暖、业绩高增长与出海加速，泡沫挤压之后的创新药，正以临床价值和商业成果为双翼，迎来一个更理性、更健康、也更值得期待的新起点。参考资料1.wind，万联证券研究所2.各公司官网原文标题 : 创新药中场复盘：泡沫挤压后的新起点","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509101509049784db77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509101509049784db77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","01801","01530","06160","02157","02162","01177","09995","01276","BK1141","SBHMY","BK1161","03692","06978","02228","BK1617","BK1574","01093","02269"],"gpt_icon":1},{"id":"2558866382","title":"中國生物製藥：TQB3122「PARP1抑制劑」臨牀試驗申請獲NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2558866382","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558866382?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 20:37","pubTimestamp":1754915832,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)公布，该集团自主研发的创新药TQB3122“PARP1抑...中国生物制药(01177)公布，该集团自主研发的创新药TQB3122“PARP1抑制剂”的新药临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理，拟用于治疗晚期恶性肿瘤。TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一方面，竞争性抑制PARP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811204201a4820139&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811204201a4820139&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2558355376","title":"中國生物製藥阿達木單抗在阿爾及利亞獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2558355376","media":"e公司","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558355376?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 11:23","pubTimestamp":1754882580,"startTime":"0","endTime":"0","summary":"近日，中国生物制药下属企业正大天晴生物类似药阿达木单抗（泰博维）正式获得阿尔及利亚国家药品管理局的上市批准，将为“一带一路”共建国家自身免疫疾病患者带来高品质、可负担的治疗新选择。中国国家药品监督管理局自2015年起逐步完善生物类似药审批体系，要求生物类似药需开展头对头临床等效性试验，并在获批后持续开展上市后监测。截至2024年，中国已批准20余款生物类似药，泰博维的获批上市正是成功实践者之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811112453a6dec33f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811112453a6dec33f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY","01177"],"gpt_icon":0},{"id":"2558563369","title":"中國生物製藥下跌4.48%，報7.03元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558563369","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558563369?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 10:17","pubTimestamp":1754878639,"startTime":"0","endTime":"0","summary":"8月11日，中国生物制药盘中下跌4.48%，截至10:10，报7.03元/股，成交3.03亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。8月18日，中国生物制药将披露2025财年中报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811102138a480fc19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811102138a480fc19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","SBHMY","BK1515","IE00BZ08YT58.USD","01177","IE00BZ08YS42.EUR","BK1589","BK1521","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2558658541","title":"生物醫藥行業研究報告：各部門合力推進商保建設 助力創新藥械發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2558658541","media":"平安证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558658541?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 00:00","pubTimestamp":1754841600,"startTime":"0","endTime":"0","summary":"创新药械的发展，需要数据、政策、资金等要素的深度融合，座谈会明确要打通医保数据与研发的协同通道。结合此前对商业健康险发展的政策支持，以及7月11日首次增加商业健康保险创新药目录等措施，将从资金面为我国创新药械发展带来增量。金融监督管理总局发布促进商保发展，与医保局形成合力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811164620a6df4231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811164620a6df4231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","LU2580892862.HKD","LU0405327494.USD","603259","688235","LU2148510915.USD","BK0188","LU2328871848.SGD","688046","600276","LU1997245094.SGD","LU2495084118.USD","BK0012","LU1997244956.HKD","LU1997245177.USD","399441","00512","LU1064130708.USD","BK0196","02269","BK0239","LU2580892789.USD","LU0405327148.USD","LU1969619763.USD","399265","688271","02315","06160","688293","BK0060","688687","01177","LU2488822045.USD","LU1255011170.USD","BK0183","LU1328615791.USD","BK0028","LU1655091616.SGD","01530","WXIBF","LU1064131003.USD","ONC","161726","06821","02359"],"gpt_icon":0},{"id":"2558017631","title":"醫藥行業週報：禮來口服減肥藥療效低於預期 關注中國創新減肥藥研發和出海進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2558017631","media":"爱建证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558017631?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 00:00","pubTimestamp":1754841600,"startTime":"0","endTime":"0","summary":"医药板块继续调整，跑输沪深300 指数。脑机接口迎来政策东风，七部门发布推动产业创新发展实施意见。礼来口服减肥药疗效低于预期，关注中国创新减肥药的研发和出海进展。另一方面，礼来Orforglipron 有效性不及预期，为中国小分子GLP-1 未来参与全球竞争留出了更大的发挥空间，目前恒瑞医药HRS-7535、成都闻泰VCT220、华东医药HDM1002 等已进入临床三期阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811144119a481616b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811144119a481616b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","688062","02696","688180","09606","SBHMY","09926","01541","688520","02359","02268","02157","09995","BK1574","06990","01276","688331","02616","06821","01177","600276","603259","688626","01877","BK1161"],"gpt_icon":0},{"id":"2558432685","title":"醫藥行業週報：中藥、生物製品、測序及醫藥商業行業觀點更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2558432685","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558432685?lang=zh_tw&edition=fundamental","pubTime":"2025-08-10 00:00","pubTimestamp":1754755200,"startTime":"0","endTime":"0","summary":"2）疫苗：建议关注产品销售改善、创新管线进展及股权变更进展。2025年下半年我们重点关注的是药品和耗材集采政策优化、多元化支付及医疗服务价格改革。④关注中药、药店、流通、医疗服务及疫苗等行业经营触底回升节奏及长期转型升级方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810161622a6dd937f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810161622a6dd937f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","688137","00013","600594","03347","600085","688739","BK1587","600535","02359","603939","600080","600557","603716","BK1588","688163","605199","600272","600422","BK1574","603456","603590","603883","600572","HCM","688687","600479","01099","600998","600129","688278","603567","600222","WXIBF","688266","01801","600332","603368","603259","603858","600518","600771","603122","600436","600829","01177","603233","688180","600329","688488","600351","600833","688114","600713","603882","09926","688136","600993","06821","603139","688276","605266","603392","688520","600976","600285","600161","601607","600671","688293","SBHMY","688185","688177","688336","09939","603439","600276","600538","600511","01276","600750","600566","02269","600867","600252","688443","BK1161","603108","603896","600211","BK1191","688670","03320","02607","688271"],"gpt_icon":0},{"id":"2557548550","title":"中國生物製藥8月7日成交額為131.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557548550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557548550?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 13:59","pubTimestamp":1754632778,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，中国生物制药成交额为131.00美元，当日成交量为7.00股。中国生物制药于2025年8月7日涨0.0%，报18.65美元，该股过去5个交易日涨0.0%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808135946a47c8373&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808135946a47c8373&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SBHMY"],"gpt_icon":0},{"id":"2557031554","title":"【研報】生物製藥板塊深度分析報告：資本介入、政策支持與研發驅動","url":"https://stock-news.laohu8.com/highlight/detail?id=2557031554","media":"上市公司网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557031554?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 17:59","pubTimestamp":1754560796,"startTime":"0","endTime":"0","summary":"外资持续增持：北向资金在2025年二季度增持生物医药板块120.65亿元，药明康德作为行业龙头，其A股估值优势成为外资配置重点。药明康德凭借全球化布局，其临床阶段项目与国际药企合作频繁，有望受益于政策对国际化研发的支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807185721a6d8a275&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807185721a6d8a275&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2495084118.USD","LU1997244956.HKD","02359","LU1934453819.USD","BK0216","688428","603716","LU1979443071.USD","LU1997245094.SGD","688221","LU0456842615.SGD","01801","09969","SBHMY","688202","159982","LU2488822045.USD","LU2328871848.SGD","LU1997245177.USD","01177","603259","399300","LU1969619763.USD"],"gpt_icon":0},{"id":"2557827315","title":"中國生物製藥下跌2.93%，報7.28元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557827315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557827315?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 10:34","pubTimestamp":1754534070,"startTime":"0","endTime":"0","summary":"8月7日，中国生物制药盘中下跌2.93%，截至10:21，报7.28元/股，成交3.01亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。8月18日，中国生物制药将披露2025财年中报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710395794d4a632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710395794d4a632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","BK1191","01177","BK1521","SBHMY","BK1589"],"gpt_icon":0},{"id":"2557547374","title":"中國生物製藥：羅伐昔替尼Ⅲ期試驗正招募受試者","url":"https://stock-news.laohu8.com/highlight/detail?id=2557547374","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557547374?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 18:42","pubTimestamp":1754476965,"startTime":"0","endTime":"0","summary":"【8月6日中国生物制药罗伐昔替尼Ⅲ期临床试验启动受试者招募】8月6日，中国生物制药公告透露，罗伐昔替尼用于治疗中重度cGVHD的Ⅲ期临床试验，目前正处于受试者招募阶段。该集团表示，将加快罗伐昔替尼的全球临床开发进程，以便尽早为全球患者提供更优质的治疗方案。本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806200217973763eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806200217973763eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","01177","BK1515","IE00BZ08YS42.EUR","BK1521","IE00BZ08YR35.GBP","SBHMY","BK1191","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2557268133","title":"國藥之光安羅替尼領銜 中國生物製藥13項肺癌成果閃耀世界舞台","url":"https://stock-news.laohu8.com/highlight/detail?id=2557268133","media":"鲁网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557268133?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 15:16","pubTimestamp":1754464573,"startTime":"0","endTime":"0","summary":"2025年世界肺癌大会即将在巴塞罗那揭幕，中国生物制药将以13项安罗替尼研究成果强势登陆。作为中国原研多靶点抗血管生成药物的“国药之光”，安罗替尼在非小细胞肺癌、小细胞肺癌及恶性胸膜间皮瘤等领域的创新疗法将集中亮相，彰显中国生物制药在肺癌精准治疗领域的全球竞争力。中国生物制药持续引领小细胞肺癌治疗领域的方案革新。中国生物制药此次亮相WCLC的13项研究，是继2025年ASCO年会12项口头报告创纪录展示后的又一创新力作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061520219736f9f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061520219736f9f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","IE00BZ08YT58.USD","BK1191","BK1521","BK1515","IE00BZ08YS42.EUR","01177","BK1589","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2557340249","title":"中國生物製藥8月5日成交額為261.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557340249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557340249?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 13:47","pubTimestamp":1754459258,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，中国生物制药成交额为261.00美元，当日成交量为14.00股。中国生物制药于2025年8月5日涨0.0%，报18.65美元，该股过去5个交易日涨0.0%，年初至今涨126.39%，过去60日涨98.87%。中国采用先进的现代化中国和生物医学技术，以研究，开发，制造和销售各种中药和化学药品。该公司的产品可分为肝炎和心脑血管疾病这两大治疗类别。该公司通过国际伙伴关系积极寻求合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806134745a477ff67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806134745a477ff67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}]}}